Jacob D. Soumerai

Poster presented at ASH 2022 describing the potential for combining BCL2i and BTKi in patients with non-Hodgkin’s lymphoma (NHL), including separate cohorts for mantle cell lymphoma (MCL) and Waldenström’s macroglobulinemia (WM).

BeiGene

Factsheet describing the treatment of Waldenström’s macroglobulinemia (WM) by inhibiting BTK.

BeiGene

Slide kit describing the treatment of Waldenström’s macroglobulinemia (WM) by inhibiting BTK.

Chat with BeiGene

Close